Cartesian Therapeutics
Most recent annual filing: 2026-03-09
- Descartes-08 AURORA topline1Q 2027Descartes-08 AURORA topline, 1Q 2027, thesis-defining
- Descartes-08 HELIOS readout1H 2027Descartes-08 HELIOS readout, 1H 2027, notable
- Cartesian Therapeutics corporate update2027Cartesian Therapeutics corporate update, 2027, routine
- Cartesian Therapeutics corporate financing1H 2027Cartesian Therapeutics corporate financing, 1H 2027, routine
- Descartes-08 TRITON pivotal interimmid-to-late 2027Descartes-08 TRITON pivotal interim, mid-to-late 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
Descartes-08
DC-08Descartes-15
Technology platforms
tLNP · WestGene BioPharma
Targeted lipid nanoparticle (tLNP) delivery platform owned by WestGene BioPharma; used to deliver mRNA payloads in vivo for BCMA-directed T-cell engineering; focus area: autoimmune diseases including myasthenia gravis
Targets: BCMA
tLNPs · WestGene BioPharma
WestGene's proprietary targeted lipid nanoparticles platform for in vivo mRNA delivery; used to deliver Cartesian's mRNA payloads including anti-BCMA CAR constructs for in vivo CAR-T engineering in autoimmune diseases; focus on eliminating ex vivo manufacturing
Targets: BCMA
Discontinued (1)
- Descartes-08 — Systemic Lupus Erythematosus · Company decided to no longer pursue development in SLE to prioritize MG and myositis
Biotech Distilled coverage (4)
- 2026-08-07 UPDATE: Cartesian Therapeutics (RNAC) - The Quarter That Repriced the Debt
- 2026-06-09 UPDATE: Cartesian Therapeutics (RNAC) - The In Vivo Option Just Got a Clinical Timeline
- 2026-05-27 UPDATE: Cartesian Therapeutics (RNAC) - The Dilution Gap Just Closed 🔒 Paid
- 2026-05-25 Cartesian Therapeutics (RNAC) — Scientific Deep Dive for Descartes-08 and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.